The second session of the digestive tract tumor MDT launch will be held in Hara.

(Health Times reporter Ye Zhengxing) January 16, sponsored by the Chinese Physicians Association Surgical Branch MDT Special Committee, Heilongjiang Provincial Medical Association, Harbin Medical University Affiliated Oncology Hospital hosted the second session of the digestive tract cancer multidisciplinary treatment (MDT) exchange of experience and academic seminar and Sanofi "with you" digestive tract tumor MDT 2016 launch meeting held in Harbin. Nearly 100 experts from more than 40 hospitals in China attended the meeting to discuss the promotion and application of the MDT model of digestive tract tumor, and strive for optimal treatment results for colorectal cancer patients and improve the quality of life.
Professor Shen Lin of Beijing Cancer Hospital and four other experts introduced the gastrointestinal tumor MDT
in recent years, colorectal cancer has become the third highest incidence of malignant tumors in the world. The incidence of colorectal cancer in China is on the rise, with more than 250,000 cases and about 140,000 deaths per year. Colorectal cancer is a systemic disease, can not be cured by a single discipline, a single treatment, the need for organic and orderly combination of surgery, chemotherapy, radiotherapy, targeted treatment and other treatment methods.
"multidisciplinary comprehensive treatment (MDT), in short, 'three solids'," said Professor Zhang Yanqiao, vice president of Harbin Medical University Affiliated Oncology Hospital, MDT is a relatively fixed group of experts from more than two disciplines who come together at a fixed time and place to discuss and form a resolution on diagnosis and treatment for patients with an organ or systemic disease.
, Professor Shen Lin, vice president of Beijing Cancer Hospital and chairman of the MDT Special Committee of the Chinese Physicians Association, said the key to the MDT treatment model is that its assessment and treatment of each patient is pre-planned and planned, so that the limitations of the lack of knowledge of other specialists can be avoided, so that patients can get full-name medical care before the start of cancer treatment.
MDT model is suitable for patients with primary and re-diagnosis of colorectal cancer, especially those who relapse or attend multiple metastases. Taking colorectal cancer liver metastasis as an example, preoperative chemotherapy can give patients who could not be removed the opportunity to operate, and postoperative assisted therapy can reduce the rate of recurrence and metastasis after surgery. "MDT therapy is not only an improvement of treatment, but also a change in the concept of treatment. In terms of long-term outcomes, MDT can significantly improve the five-year survival rate of patients with colorectal cancer liver transfer and reduce the recurrence rate of patients with late-stage colorectal cancer, improving their quality of life," said Professor Liu Yunpeng of First Hospital affiliated with The Chinese Medical University.
in the multidisciplinary comprehensive treatment of colorectal cancer, chemotherapy is one of the important components, unfortunately, many patients still have excessive fear or even psychological bias about chemotherapy, the understanding of chemotherapy has a single pursuit of targeted cutting-edge treatment and ignore the combination of chemotherapy treatment, clinical chemotherapy drug "inadequate", early diagnosis of awareness is not enough.
"The adverse reactions produced by chemotherapy, most of which can be controlled, we need to clearly inform the patient will face, and what can be obtained from it, to provide patients with all-round physical and mental care, to help patients scientifically manage diseases", Zhejiang University Of Medicine affiliated with the Second Hospital Vice President Professor Zhang Su-zhang pointed out that chemotherapy drugs are the cornerstone of anti-cancer treatment, clinical application time is long, effective, and high safety, cost, efficiency ratio is reasonable. A reasonable chemotherapy regimen, an appropriate dose of the drug, and adequate chemotherapy cycles are all critical.
.